Cell therapy for Parkinson's disease: what next?
Björklund, Anders LU
and Kordower, Jeffrey H
(2013)
In Movement Disorders
28(1).
p.110-115
- Abstract
- The idea to use transplants of dopamine-producing cells to substitute for the lost midbrain dopamine neurons in Parkinson's disease (PD) goes back to the 1970s. In this review we give an overview of the history of cell transplantation in animal models of PD, and summarize the experience gained from the open-label and placebo-controlled clinical trials performed so far using intrastriatal transplants of human fetal dopamine neuroblasts. Further development of this therapeutic approach face numerous challenges, for example in the development of protocols that allow generation of fully functional and safe midbrain dopamine neurons from stem cells. Based on recent promising advancements, efforts are now being made to develop standardized and... (More)
- The idea to use transplants of dopamine-producing cells to substitute for the lost midbrain dopamine neurons in Parkinson's disease (PD) goes back to the 1970s. In this review we give an overview of the history of cell transplantation in animal models of PD, and summarize the experience gained from the open-label and placebo-controlled clinical trials performed so far using intrastriatal transplants of human fetal dopamine neuroblasts. Further development of this therapeutic approach face numerous challenges, for example in the development of protocols that allow generation of fully functional and safe midbrain dopamine neurons from stem cells. Based on recent promising advancements, efforts are now being made to develop standardized and efficient protocols, and adapt these protocols to good laboratory practice (GLP)/good manufacturing practice (GMP) conditions, to move this technology closer to clinical translation. © 2013 Movement Disorder Society. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3560096
- author
- Björklund, Anders
LU
and Kordower, Jeffrey H
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Movement Disorders
- volume
- 28
- issue
- 1
- pages
- 110 - 115
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000314995300013
- pmid:23390097
- scopus:84873450271
- pmid:23390097
- ISSN
- 0885-3185
- DOI
- 10.1002/mds.25343
- language
- English
- LU publication?
- yes
- id
- 8fa2236f-c052-433c-a72e-6591b798622a (old id 3560096)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23390097?dopt=Abstract
- date added to LUP
- 2016-04-04 07:48:09
- date last changed
- 2022-05-16 20:30:33
@article{8fa2236f-c052-433c-a72e-6591b798622a,
abstract = {{The idea to use transplants of dopamine-producing cells to substitute for the lost midbrain dopamine neurons in Parkinson's disease (PD) goes back to the 1970s. In this review we give an overview of the history of cell transplantation in animal models of PD, and summarize the experience gained from the open-label and placebo-controlled clinical trials performed so far using intrastriatal transplants of human fetal dopamine neuroblasts. Further development of this therapeutic approach face numerous challenges, for example in the development of protocols that allow generation of fully functional and safe midbrain dopamine neurons from stem cells. Based on recent promising advancements, efforts are now being made to develop standardized and efficient protocols, and adapt these protocols to good laboratory practice (GLP)/good manufacturing practice (GMP) conditions, to move this technology closer to clinical translation. © 2013 Movement Disorder Society.}},
author = {{Björklund, Anders and Kordower, Jeffrey H}},
issn = {{0885-3185}},
language = {{eng}},
number = {{1}},
pages = {{110--115}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Movement Disorders}},
title = {{Cell therapy for Parkinson's disease: what next?}},
url = {{http://dx.doi.org/10.1002/mds.25343}},
doi = {{10.1002/mds.25343}},
volume = {{28}},
year = {{2013}},
}